Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker

ATLANTA , June 10, 2026 /PRNewswire/ -- Huxley Medical , a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, today introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment model that enables clinics to dispense SANSA at patient visits, and hypoxic burden, an additional measure of cardiovascular strain associated with sleep apnea. Both additions build on SANSA's existing FDA clearances as the only multi-diagnostic monitor able to assess electrocardiograms (ECG) , obstructive sleep apnea, and central sleep apnea with a single chest-worn patch.